Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies (drugs and devices) designed to address the significant needs of critically ill patients. The company’s lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package is marketed in the USA, Puerto Rico, Canada, Australia, Mexico and Japan
Company Details
- Employees
- 98
- Founded
- -
- Address
- The Significant Needs Of Critically Ill Patients. The Company’s Lead Product Is Inomax® (Nitric Oxide) For Inhalation
- Phone
- 908-238-6600
- in****@****ria.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- ikaria.com
Ikar Questions
Ikar's helpline number is 908-238-6600
Ikar's website is ikaria.com
Ikar's LinkedIn profile is https://www.linkedin.com/company/ikar
Ikar has
98 employees.
View email and phone details for 98
employees at Ikar.
Ikar's industry is
Pharmaceutical Manufacturing
Ikar's support email address is info@ikaria.com
Ikar's categories are Pharmaceutical Manufacturing
Ikar's founding year is 2007
